Abstract 77P
Background
Radical lymph nodes (LNs) dissection is the cornerstone of gastric cancer (GC) surgical treatment. Indocyanine green (ICG) fluorescence imaging-guided lymphadenectomy has been proven to be effective in increasing the number of LNs retrieved in laparoscopic gastrectomy (LG) for GC. However, the long-term oncological efficacy of ICG fluorescence imaging in LG remains uncertain. This randomized clinical trial was conducted to evaluate the long-term oncological efficacy of ICG imaging-guided laparoscopic lymphadenectomy for GC.
Methods
The study was an open-label, randomized clinical trial conducted at a tertiary referral teaching hospital in China. A total of 266 eligible patients with potentially resectable GC (cT1-4a, N0/+, M0) without bulky nodes or distant metastases were enrolled from November 2018 to July 2019. Patients were randomly (1:1 ratio) assigned to the ICG group or the non-ICG group.
Results
Among 266 patients, 258 (97.0%; mean age, 58.9 years; 85 [32.9%] women) completed the study. The mean (SD) total number of LNs retrieved in the ICG group was 50.5 (15.9), which was significantly more than that of the non-ICG group (42.0 [10.3], P < 0.001). The 3-year disease-free survival (DFS) of the ICG group and the non-ICG group were 81.4% and 68.2%, respectively, with an absolute risk difference of 13.2% (Log-rank P = 0.012). The 3-year overall survival (OS) in the ICG group was 86.0%, which was significantly higher than that in the non-ICG group (73.6%; Log-rank P = 0.015). Cox multivariate analysis showed ICG was the independent protective factor for both OS and DFS (OS: HR=0.49, 95%CI: 0.27-0.91; P = 0.023; DFS: HR=0.51, 95%CI: 0.30-0.87; P = 0.014).There were differences in overall recurrence patterns between the ICG and non-ICG groups within 3 years after surgery (17.9% vs. 31.0%, P = 0.014).
Conclusions
For patients with resectable GC, ICG fluorescence imaging-guided laparoscopic lymphadenectomy showed better long-term oncological efficacy than conventional LN dissection, especially in patients undergoing total gastrectomy. These findings provided encouraging evidence for the ongoing, randomized, phase 3, CLASS-11 study (NCT03875235).
Clinical trial identification
NCT03875235.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
109P - Economic evaluation of second-line treatment for patients with esophageal squamous cell carcinoma: A systematic review
Presenter: Gagandeep Kaur
Session: Poster viewing 02
110P - Neutrophil to lymphocyte ratio as a predictor of poor prognosis in advanced esophageal cancer
Presenter: Chaichana Chantharakhit
Session: Poster viewing 02
111P - Bicentric real-life analysis of the molecular portrait of patients with early onset metastatic biliary tract cancer
Presenter: Theresa Schmalfuss
Session: Poster viewing 02
112P - Prognostic role of sarcopenia before neoadjuvant chemoradiotherapy in patients with esophageal cancer: A retrospective study
Presenter: Mastaneh Sanei
Session: Poster viewing 02
113P - Brain metastases in esophageal cancer patients who have been treated with neoadjuvant immunotherapy plus chemotherapy: An inconsiderable complication
Presenter: Jun Liu
Session: Poster viewing 02
114P - Risk factors for oesophageal fistula: A life-threatening complication of treatment for oesophageal cancer
Presenter: Reo Omori
Session: Poster viewing 02
115P - Human epidermal growth factor receptor-2 (HER-2) expression status in patients with cholangiocarcinoma
Presenter: Thanit Imemkamon
Session: Poster viewing 02
116P - Spleen as an organ at risk (OAR) in adjuvant chemoradiotherapy of gastric cancer: Retrospective dosimetric single institutional experience
Presenter: Preethi Shetty
Session: Poster viewing 02
117P - Immunoprofile of adenosquamous carcinoma in gastric cancer
Presenter: Cheng-Han Wu
Session: Poster viewing 02
118P - Association between stomach cancer with behavioral and dietary factors: A case control study from Nepal
Presenter: Arun Shahi
Session: Poster viewing 02